Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Candicidin is a polyene antifungal antibiotic obtained from the bacterium Streptomyces griseus. It is primarily used for the topical (intravaginal) treatment of vulvovaginal candidiasis and is especially effective against Candida albicans. The mechanism of action involves binding irreversibly to ergosterol in the fungal cell membrane. This disrupts membrane integrity by altering permeability and causing intracellular ion imbalance, ultimately leading to cell death. Candicidin was named for its high activity against Candida species and has been reported as more effective than amphotericin B in some contexts[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on candicidin.